Rain Therapeutics Inc. (RAIN): Price and Financial Metrics
GET POWR RATINGS... FREE!
RAIN Stock Price Chart Interactive Chart >
RAIN Price/Volume Stats
|Current price||$8.98||52-week high||$14.48|
|Prev. close||$9.68||52-week low||$2.15|
|Day high||$10.47||Avg. volume||286,473|
|50-day MA||$8.28||Dividend yield||N/A|
|200-day MA||$5.82||Market Cap||238.55M|
Rain Therapeutics Inc. (RAIN) Company Bio
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is RAIN-32, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing RAIN-32 that has completed Phase II clinical trial in liposarcoma, Phase I clinical trial in solid tumors, and Phase II clinical trial in intimal sarcoma, as well as RAD52 for tumors, including breast, ovarian, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
Most Popular Stories View All
RAIN Latest News Stream
|Loading, please wait...|
RAIN Latest Social Stream
View Full RAIN Social Stream
Latest RAIN News From Around the Web
Below are the latest news stories about RAIN THERAPEUTICS INC that investors may wish to consider to help them evaluate RAIN as an investment opportunity.
– Intermittent dosing of milademetan, an inhibitor of the p53-MDM2 complex, potentially exhibits an avenue to address historical issues with cytopenias with this class of compounds– – Phase 1 data in advanced dedifferentiated liposarcoma provides foundation for the registrational Phase 3 MANTRA trial – NEWARK, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, mi
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
The oncology company's stock has been correcting sideways for a few months but seems poised for renewed gains.
NEWARK, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”) (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that it will change its name to Rain Oncology Inc. effective tomorrow, December 30, 2022, to better reflect the company's focus on addressing unmet needs for cancer patients
NEWARK, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that it will be participating in J.P. Morgan’s 41st Annual Health Care Conference, being held January 9 – 12, 2023, in San Francisco, CA. Avanish Vellanki, chief executive officer o
RAIN Price Returns